More than 20 researchers from Huntsman Cancer Institute (HCI) at the University of Utah made their mark on the American Association of Cancer Research (AACR) Annual Meeting this year. Held in Washington, D.C., the convention drew more than 21,500 cancer researchers from all over the world. Scientists attended sessions on topics from immunotherapy to precision medicine. About 15 researchers from HCI presented posters in the main conference hall, on a wide range of topics. ... Read More
Identifying Possible Cancer-Fighting Agents
The goal of the Center for Investigational Therapeutics (CIT) laboratory program is to identify clinical candidate compounds as possible cancer-fighting agents to be considered for Phase I (first-in-man) clinical trials.
Developing & Screening Compounds
Researchers with the CIT work to discover new agents that can be developed into drugs. Chemists in our laboratory discover and develop compounds they believe can be used to target cancer cells. Our team can screen thousands of experimental compounds each year using both cell and tumor-based assays.
Our skilled researchers use cutting-edge techniques, such as lead compound identification and proof-of-mechanism studies, to rapidly advance compounds from discovery to clinical candidates. Our team has years of experience with approved anticancer agents and understands the efficacy and toxicity profiles for approved chemotherapeutics. This allows detailed evaluation of novel agents in combination with standard therapeutic courses of therapy.
Features of the preclinical program fall under two general categories:
- Computational and medicinal chemistry; including computer-aided drug design
- Cancer biology; including assay development, screening, biomarker identification and in vivo models for preclinical efficacy and imaging studies
Our laboratory and clinical teams have been involved in developing some of the most important cancer drugs used today.
News & Blog
Doctors at Huntsman Cancer Institute (HCI) are discovering some treatments that work for one type of cancer may also work for another, if it has similar mutations, or genetic changes. Genetic changes, or mutations, change some normal cells in the body into cancer cells which can grow and multiply. There are more than 100 types of cancer, which means many different ways to treat cancer are needed. Most cancers are named for the part of the body where they started.... Read More
There’s a new treatment for patients with ALK+ (positive) non-small-cell lung cancer (NSCLC), which can occur in non-smoking lung cancer patients. Previously in clinical trial at Huntsman Cancer Institute, the new drug, Zykadia™/ ceritinib, is part of a new generation of treatments that targets a specific genetic defect in the tumor. Dr. Sunil Sharma discusses the medication and its uses for treating this cancer.... Read More
Huntsman Cancer Institute (HCI) is known throughout the world for our discovery of cancer-causing genes, innovation related to clinical care and research for families affected by cancer, and the impact on quality of life for those at increased risk of developing the disease.... Read More